CRISPR Highlights from ASH Meeting 2021
Dec. 22, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Emendo Biotherapeutics
Main focus: Gene editing for the treatment of genetic diseases and cancer
Company stage: Pre-clinical
Diseases: Severe congenital neutropenia, bone marrow failure, retinitis pigmentosa, cone-rod dystrophy, macular dystrophy, cancer
Genome editing tool: CRISPR
Funding stage: Private
Location: New York, USA
Website: https://www.emendobio.com
Pipeline: https://www.emendobio.com/pipeline/
Emendo Biotherapeutics is a next-generation gene-editing company focused on developing novel nucleases for its proprietary CRISPR systems. The nucleases are being developed for enhanced precision and effiency, and are based on the company's proprietary OMNI technology platforms. The company focuses on diseases within haematology as well as ophthalmology and cancer. Emendo was was recently acquired by AnGes, but will remain an independent subsidiary of the company.
